FEDERAL COURT OF AUSTRALIA
Novartis AG v Pharmacor Pty Limited (No 2) [2023] FCA 963
File number: NSD 506 of 2023 Judgment of: YATES J Date of judgment: 16 August 2023 Catchwords: PRACTICE AND PROCEDURE – patents – interlocutory application for question to be heard separately pursuant to r 30.01(1) of the Federal Court Rules 2011 (Cth) – where proposed separate question concerns the relevant time at which a patent applicant’s knowledge of the best method is to be fixed for the purposes of s 40(2)(a) of the Patents Act 1990 (Cth) – overarching purpose of civil practice and procedure provisions – determination of the costs of an additional interlocutory application no longer pressed Legislation: Federal Court of Australia Act 1976 (Cth) s 37M
Patents Act 1990 (Cth) ss 40, 192
Federal Court Rules 2011 (Cth) rr 21.01, 30.01
Cases cited: GlaxoSmithKline Consumer Healthcare Investments (Ireland) (No 2) Ltd v Generic Partners Pty Ltd [2018] FCAFC 71; 264 FCR 474
Les Laboratoires Servier v Apotex Pty Ltd [2016] FCAFC 27; 247 FCR 61
Novartis AG v Pharmacor Pty Ltd [2023] FCA 804
Pfizer Overseas Pharmaceuticals v Eli Lilly & Co [2005] FCAFC 224; 225 ALR 416
Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Number of paragraphs: 66 Date of hearing: 11 August 2023 Counsel for the Applicants: Mr T Cordiner KC Solicitor for the Applicants: Clayton Utz Counsel for the Respondent: Mr J Cooke SC and Mr D Larish Solicitor for the Respondent: Ashurst Australia ORDERS
NSD 506 of 2023 BETWEEN: NOVARTIS AG
First Applicant
NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED
Second Applicant
AND: PHARMACOR PTY LIMITED
Respondent
ORDER MADE BY:
YATES J
DATE OF ORDER:
16 AUGUST 2023
THE COURT ORDERS THAT:
1.The interlocutory application dated 11 July 2023 as amended by the amended interlocutory application dated 14 July 2023, filed by the applicants (the first interlocutory application), be dismissed.
2.The applicants pay the respondent’s costs of the first interlocutory application.
3.The interlocutory application dated 26 July 2023, filed by the respondent (the second interlocutory application), be dismissed.
4.There be no order for costs in respect of the second interlocutory application, with each party to bear its own costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
YATES J:
INTRODUCTION
There are two interlocutory applications before me.
The first is an amended interlocutory application filed by the applicants in the principal proceeding, Novartis AG and Novartis Pharmaceuticals Australia Pty Limited (Novartis Australia) (I will refer to both as, simply, Novartis), seeking the separate determination, pursuant to r 30.01(1) of the Federal Court Rules 2011 (Cth) (the Rules), of whether certain paragraphs of the amended statement of cross-claim filed by the respondent, Pharmacor Pty Limited (Pharmacor), and Pharmacor’s application for a declaration of invalidity in respect of claim 1 of Patent No. 2003206738 (the patent), should be…
Keep reading for free
Create a free CaseChat account to read Novartis AG v Pharmacor Pty Limited (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2023] FCA 963
- Decision Date
CaseChat Overview and Summary
The court determined that the overarching purpose of the civil practice and procedure provisions was to facilitate the just resolution of disputes according to law as quickly, inexpensively, and as efficiently as possible. The court noted that the applications arose from a previous case management hearing where the possibility of additional interlocutory applications had been raised. The court observed that circumstances had changed since that hearing, with Pharmacor narrowing its discovery request and Novartis having already provided the ordered discovery without finding any relevant documents. The court concluded that, given these developments and the potential for further interlocutory proceedings, it was in the interests of justice to dismiss both applications without awarding costs.
In summary, the Federal Court dismissed both interlocutory applications, with the first application being dismissed on the costs of the respondent and the second application having no order for costs, each party bearing its own costs. This decision underscores the importance of considering the overarching purpose of civil procedure provisions when dealing with interlocutory matters, particularly in the context of patent disputes.
Orders
Orders of the court
1. The interlocutory application dated 11 July 2023 as amended by the amended interlocutory application dated 14 July 2023, filed by the applicants (the first interlocutory application), be dismissed.
2. The applicants pay the respondent’s costs of the first interlocutory application.
3. The interlocutory application dated 26 July 2023, filed by the respondent (the second interlocutory application), be dismissed.
4. There be no order for costs in respect of the second interlocutory application, with each party to bear its own costs.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi
Legal Principle Established
Fourthly, Pharmacor says that, if I were to accede to Novartis’s interlocutory application, and if the proposed question were to be determined adversely to it, it would seek leave to appeal. Although its application would be made on an expedited basis, it is possible that seeking leave to appeal could bring into train events that could jeopardise the present listing of the trial to commence on 8 April 2024, or at least disrupt the orderly conduct of that trial.Consideration Section 37M of the Federal Court of Australia Act 1976 (Cth) requires me to approach the determination of this interlocutory application having regard to the overarching purpose of the Court’s civil practice and procedure provisions, which is to facilitate the just resolution of disputes according to law as quickly, inexpensively, and as efficiently as possible, bearing in mind a number of considerations, including: (a) the just determination of all proceedings before the Court; (b) the efficient use of the judicial and administrative resources available for the purposes of the Court; (c) the efficient disposal of the Court’s overall caseload; (d) the disposal of all proceedings in a timely manner; and (e) the resolution of disputes at a cost that is proportionate to the importance and complexity of the matters in dispute. The genesis of the present application appears to be a comment I made at a case management hearing on 6 July 2023 in the context of the parties raising the prospect of a number of interlocutory applications being filed. These concerned a complaint by Novartis about the generality of Pharmacor’s pleading of the first strand of its best method challenge, and Pharmacor’s expressed intention to seek discovery referable to Novartis AG’s knowledge of the best method as at the Date of Filing, the Dates of Amendment, and the Date of Grant. At that time I raised for consideration whether the determination of the relevant time at which a patent applicant’s knowledge is to be fixed for the purposes of s 40(2)(a) of the Act (in its relevant form) might best be considered in the context of the determination of a separate question, rather than in the context of a dispute about pleadings or a dispute about discovery. I should also say that, at that time, Novartis was not prepared to identify, with reference to the complete specification, what it was proposing to contend was the best method known to Novartis AG at any date. Since that case management hearing, circumstances have changed considerably. First, although, at that time, Pharmacor was seeking discovery in respect of the first strand of its best method challenge with reference to two time periods— 16 January 1998 to the Date of Filing, and between the Date of Filing and the Date of Grant—Pharmacor subsequently confined its interlocutory application for discovery to the first of those periods: Novartis AG v Pharmacor Pty Ltd [2023] FCA 804. Secondly, Novartis AG and Novartis Australia have now given discovery with respect to the category ordered on 14 July 2023. As I have noted, no documents were discovered.